Wegovy Becomes India's First GLP-1 Therapy Approved for MASH, Offering New Hope for Patients with Advanced Fatty Liver Disease

In a major advancement for India's healthcare sector, Novo Nordisk India has received approval from the Central Drugs Standard Control Organisation (CDSCO) for a new indication of its blockbuster medicine Wegovy (semaglutide 2.4 mg) to treat a severe form of fatty liver disease known as Metabolic Dysfunction-Associated Steatohepatitis (MASH). The approval marks a significant milestone as Wegovy becomes the first and only GLP-1 receptor agonist approved in India for this condition.

The approval allows Wegovy to be prescribed for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis, alongside a calorie-restricted diet and increased physical activity. The decision expands the medicine's role beyond obesity and type 2 diabetes management, offering physicians a much-needed treatment option for one of the fastest-growing liver diseases linked to metabolic disorders.

With obesity, diabetes, and fatty liver disease increasing rapidly across India, the approval is expected to improve treatment options while drawing greater attention to the importance of early diagnosis, weight management, and lifestyle modification.

Understanding MASH: A Growing Health Challenge

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is an advanced stage of fatty liver disease caused by excessive fat accumulation in the liver.

Unlike simple fatty liver, MASH is characterized by:

• Chronic liver inflammation

• Damage to liver cells

• Progressive liver scarring (fibrosis)

• Declining liver function

If left untreated, the condition may progress to:

• Cirrhosis

• Liver failure

• Liver cancer

• Need for liver transplantation

Because symptoms often remain silent during the early stages, many patients are diagnosed only after significant liver damage has already occurred.

Why the CDSCO Approval Is Significant

The latest approval represents a major breakthrough because treatment options for MASH have historically been limited.

With this approval:

• Wegovy becomes India's first GLP-1 receptor agonist approved for MASH.

• Doctors gain access to a scientifically validated treatment option.

• Patients with advanced fatty liver disease receive an additional therapeutic choice.

• The focus shifts toward managing both obesity and liver disease simultaneously.

The decision also aligns India with several global healthcare markets where semaglutide-based therapies are increasingly being used for broader metabolic disease management.

How Wegovy Works

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a naturally occurring hormone responsible for regulating appetite and blood sugar.

The medicine works by:

• Reducing appetite

• Slowing stomach emptying

• Improving insulin sensitivity

• Supporting sustainable weight loss

• Reducing fat accumulation in the liver

• Improving metabolic health

Weight reduction plays an important role in slowing the progression of MASH and improving overall liver function.

Lifestyle Modification Remains Essential

Although Wegovy provides a new treatment option, medical experts emphasize that medication should complement—not replace—healthy lifestyle habits.

Patients are advised to:

• Follow a calorie-controlled diet

• Exercise regularly

• Maintain healthy body weight

• Control blood sugar levels

• Reduce cholesterol

• Avoid excessive alcohol consumption

Long-term disease management depends on combining medication with sustained lifestyle changes.

India Faces Rising Cases of Fatty Liver Disease

India is witnessing a sharp increase in lifestyle-related metabolic disorders.

Contributing factors include:

• Rising obesity rates

• Type 2 diabetes

• Sedentary lifestyles

• Poor dietary habits

• Urbanization

• Metabolic syndrome

Healthcare experts estimate that fatty liver disease now affects millions of Indians, making it one of the country's fastest-growing chronic health concerns.

Without timely intervention, many patients remain at risk of developing irreversible liver damage.

Expanding Role of GLP-1 Medicines

Originally developed for diabetes management, GLP-1 receptor agonists have evolved into an important class of medicines addressing multiple metabolic conditions.

Clinical research has demonstrated benefits including:

• Better blood sugar control

• Significant weight reduction

• Lower cardiovascular risk

• Improved liver health

• Reduced inflammation

The latest approval further expands the therapeutic importance of GLP-1 medicines in managing chronic metabolic diseases.

Potential Benefits for Patients

Patients diagnosed with eligible forms of MASH may experience several potential benefits from treatment.

These include:

• Reduction in liver fat

• Slower progression of fibrosis

• Better metabolic control

• Improved body weight

• Lower cardiovascular risk

• Enhanced overall quality of life

Treatment decisions, however, should always be individualized under the supervision of qualified healthcare professionals.

Impact on India's Healthcare Sector

The approval reflects India's growing emphasis on preventive healthcare and chronic disease management.

Healthcare providers are increasingly focusing on:

• Early diagnosis

• Obesity management

• Lifestyle intervention

• Diabetes prevention

• Comprehensive metabolic care

The availability of advanced therapies is expected to strengthen the country's ability to manage the long-term burden of obesity-related illnesses.

Novo Nordisk Strengthens Its Position

Novo Nordisk continues to expand its presence in India's rapidly growing metabolic care market.

The company already maintains a strong portfolio across:

• Diabetes treatment

• Obesity management

• Endocrinology

• Chronic metabolic disorders

The additional approval broadens Wegovy's commercial potential while reinforcing the company's leadership in metabolic healthcare.

Challenges Remain

Despite the approval, several challenges may influence the pace of adoption.

These include:

• Cost of therapy

• Patient awareness

• Early disease detection

• Availability of specialist care

• Long-term treatment adherence

Expanding awareness among both physicians and patients will be essential to improving outcomes.

Growing Market for Metabolic Disease Therapies

The global market for obesity and metabolic disease treatments is expanding rapidly.

Key growth drivers include:

• Rising obesity prevalence

• Increasing diabetes cases

• Aging population

• Better disease awareness

• Advances in biotechnology

• Growing healthcare expenditure

India is expected to become one of the largest long-term growth markets for therapies targeting metabolic disorders.

Market Outlook

The approval of Wegovy for treating MASH represents a significant advancement in India's healthcare ecosystem, where obesity, diabetes, and fatty liver disease are emerging as major public health challenges. As awareness improves and diagnostic capabilities expand, demand for innovative therapies addressing metabolic disorders is expected to grow steadily over the coming years.

For the pharmaceutical industry, the approval underscores the increasing importance of medicines that deliver benefits across multiple disease areas. Companies investing in obesity, diabetes, cardiovascular health, and liver disease are likely to benefit from rising healthcare demand and expanding treatment opportunities in both developed and emerging markets.

Investor Takeaway

Novo Nordisk's latest CDSCO approval significantly expands the clinical scope of Wegovy, positioning the drug as India's first GLP-1 therapy approved for treating non-cirrhotic MASH. The approval strengthens the company's presence in one of the fastest-growing therapeutic segments while addressing a major unmet medical need linked to obesity and metabolic disease.

For investors, the development highlights the long-term growth potential of pharmaceutical companies focused on chronic lifestyle diseases. As India's burden of obesity, diabetes, and fatty liver disease continues to rise, innovative therapies with proven clinical benefits are expected to play an increasingly important role in the country's healthcare landscape, creating sustained opportunities for both the industry and long-term shareholders.